Table 2.
Baseline characteristics | N (25[OH]D3/placebo) | 25(OH)D3 | Placebo | P value |
---|---|---|---|---|
Age ≥ 65 years | 53/53 | 13% (7) | 13% (7) | 1.0 |
Disease severity (based on the CDC criteria) | 53/53 | 68% (36) | 60% (32) | .4 |
History of chronic disorders | ||||
Hypertension | 53/53 | 34% (18) | 28% (15) | .5 |
Cardiac disorder | 53/53 | 9% (5) | 15% (8) | .4 |
Diabetes mellitus | 53/53 | 26% (14) | 21% (11) | .5 |
Immunologic | 53/53 | 4% (2) | 0 | .5a |
Liver | 53/53 | 1.9% (1) | 0 | 1.0a |
Renal | 53/53 | 4% (2) | 2% (1) | 1.0a |
Neurologic | 53/53 | 4% (2) | 0% | .5a |
Lung | 53/53 | 7.5% (4) | 13% (7) | .3 |
Lymphocytes < 800 | 52/53 | 19% (10) | 22% (12) | .6 |
Abbreviations: CDC = Centers for Disease Control and Prevention; 25(OH)D3 = 25-hydroxyvitamin D3.
At baseline, there was no significant difference in the history of chronic disorders including hypertension; cardiovascular disorder; diabetes mellitus; lung, liver, and kidney diseases; and neurologic and immunologic disorders.
Fisher exact test.